Updated efficacy and > 1-y follow up from IMvigor210: Atezolizumab (atezo) in platinum (plat) treated locally advanced/metastatic urothelial carcinoma (mUC).

被引：4
|
作者：
Dreicer, Robert
Hoffman-Censits, Jean H.
Flaig, Thomas W.
Grande, Enrique
Balmanoukian, Ani Sarkis
von Amsberg, Gunhild
Theodore, Christine
Chowdhury, Simon
Bracarda, Sergio
Clement, Jessica Mary
Yu, Evan Y.
Kalebasty, Arash Rezazadeh
Niegisch, Guenter
Culine, Stephane
Gordon, Michael S.
Cui, Na
Mariathasan, Sanjeev
Legrand, Fatema A.
Abidoye, Oyewale O.
Petrylak, Daniel Peter
机构：
[1] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA
[2] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[3] Univ Colorado, Canc Ctr, Aurora, CO USA
[4] Hosp Univ Ramon y Cajal, Dept Med Oncol, Madrid, Spain
[5] Angeles Clin & Res Inst, Los Angeles, CA USA
[6] 6Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[7] Hosp Foch, Suresnes, France
[8] Guys Hosp, London, England
[9] Kings Hosp, London, England
[10] St Thomas Hosp, London, England
[11] Osped San Donato USL8, Med Oncol, Ist Toscano Tumori, Arezzo, Italy
[12] Univ Connecticut, Ctr Hlth, Carole & Ray Neag Comprehens Canc Ctr, Farmington, CT USA
[13] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[14] Norton Canc Inst, Louisville, KY USA
[15] Heinrich Heine Univ, Dept Urol, Dusseldorf, Germany
[16] Hop St Louis, Paris, France
[17] HonorHlth Res Inst, Pinnacle Oncol Hematol, Scottsdale, AZ USA
[18] Genentech Inc, San Francisco, CA 94080 USA
[19] Roche Genentech, San Francisco, CA USA
[20] Genentech Inc, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA
[21] Yale Univ, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.4515
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4515
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study
    Loriot, Y.
    Rosenberg, J. E.
    Powles, T. B.
    Necchi, A.
    Hussain, S.
    Morales, R.
    Retz, M.
    Niegisch, G.
    Duran, I.
    Theodore, C.
    Perez-Gracia, J. L.
    Grande Pulido, E.
    Thastrom, A.
    Danner, B.
    Mariathasan, S.
    Abidoye, O.
    van der Heijden, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Post-progression outcomes from the phase 2 IMvigor210 study
    Necchi, A.
    Joseph, R. W.
    Loriot, Y.
    Hoffman-Censits, J.
    Perez Gracia, J. L.
    Petrylak, D. P.
    Zhu, Q.
    Ding, B.
    Kaiser, C.
    Rosenberg, J. E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC)
    Bellmunt, J.
    Balar, A.
    Galsky, M. D.
    Loriot, Y.
    Theodore, C.
    Grande Pulido, E.
    Castellano, D.
    Retz, M.
    Niegisch, G.
    Bracarda, S.
    Necchi, A.
    Vaishampayan, U.
    Sridhar, S.
    Eigl, B. J.
    Hussain, S.
    van der Heijden, M.
    Danner, B.
    Mariathasan, S.
    Legrand, F.
    Rosenberg, J. E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210
    Balar, Arjun Vasant
    Dreicer, Robert
    Loriot, Yohann
    Perez-Gracia, Jose Luis
    Hoffman-Censits, Jean H.
    Petrylak, Daniel Peter
    Van Der Heijden, Michiel Simon
    Ding, Beiying
    Shen, Xiaodong
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study
    Necchi, A.
    Joseph, R. W.
    Loriot, Y.
    Hoffman-Censits, J.
    Perez-Gracia, J. L.
    Petrylak, D. P.
    Derleth, C. L.
    Tayama, D.
    Zhu, Q.
    Ding, B.
    Kaiser, C.
    Rosenberg, J. E.
    ANNALS OF ONCOLOGY, 2017, 28 (12) : 3044 - 3050
  • [6] Long-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC)
    von Amsberg, G.
    Balar, A. V.
    Dreicer, R.
    Loriot, Y.
    Perez-Gracia, J. L.
    Hoffman-Censits, J. H.
    Petrylak, D. P.
    van der Heijden, M. S.
    Shen, X.
    Ding, B.
    Rosenberg, J. E.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 106 - 106
  • [7] Long-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC).
    Balar, Arjun Vasant
    Dreicer, Robert
    Loriot, Yohann
    Perez-Gracia, Jose Luis
    Hoffman-Censits, Jean H.
    Petrylak, Daniel Peter
    Van Der Heijden, Michiel Simon
    Shen, Xiaodong
    Ding, Beiying
    Ramirez-Montagut, Teresa
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [8] Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): outcomes by prior therapy
    von Amsberg, G.
    Perez-Garcia, J. L.
    Loriot, Y.
    Rosenberg, J. E.
    Powles, T.
    Necchi, A.
    Hussain, S. A.
    Morales-Barrera, R.
    Retz, M.
    Niegisch, G.
    Duran, I.
    Theodore, C.
    Grande, E.
    Thastrom, A. C.
    Li, S.
    Abidoye, O. O.
    Van Der Heijden, M. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 115 - 115
  • [9] IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).
    Hoffman-Censits, Jean H.
    Grivas, Petros
    Van der Heijden, Michiel Simon
    Dreicer, Robert
    Loriot, Yohann
    Retz, Margitta
    Vogelzang, Nicholas J.
    Perez-Gracia, Jose Luis
    Rezazadeh, Arash
    Bracarda, Sergio
    Yu, Evan Y.
    Hoimes, Christopher J.
    Bellmunt, Joaquim
    Quinn, David I.
    Petrylak, Daniel Peter
    Hussain, Syed A.
    Cui, Na
    Mariathasan, Sanjeev
    Abidoye, Oyewale O.
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [10] Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.
    Balar, Arjun Vasant
    Galsky, Matt D.
    Loriot, Yohann
    Dawson, Nancy Ann
    Necchi, Andrea
    Srinivas, Sandy
    Joseph, Richard Wayne
    Vaishampayan, Ulka N.
    Sridhar, Srikala S.
    Quinn, David I.
    Drakaki, Alexandra
    Duran, Ignacio
    Rosenberg, Jonathan E.
    Powles, Thomas
    Hoffman-Censits, Jean H.
    Cui, Na
    Mariathasan, Sanjeev
    Thastrom, Ann Christine
    Abidoye, Oyewale O.
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18)
12345